LAUSR

Introduction: People with type 2 Diabetes Mellitus (DM2) have high risk and frequency of non-alcoholic fatty liver disease (NAFLD) development. Altered liver function reflected on glycemia level and increased risk of diabetes complications. The aims of our study were try to find relationship between NAFLD, glycemic control, type of treatment and frequency of diabetes complications. Material and methods: 62 people with DM2 admitted in hospital of Republican Specialised Scientific Practical Medical Centre of Endocrinology named after acad. Y.KH. Turakulov, were observed. 32 men and 30 women among them with average age 58.9±0.58 years old and average DM2 duration was 9±2.3 years. In all observed people Body mass index (BMI), total blood count, urine check, glycemia, HbA1c, AlT, AsT, total cholesterol, triglycerides and liver ultrasound were assessed. Liver fibrosis score were calculated according to Fib4 formula. Results: NAFLD were determined in 45.8%, almost half among observed DM2 patients. There were significant differences in BMI (P<0,05), total blood platelets count (P<0,01), HbA1c (P<0,05), blood fibrinogen (P<0,05), triglycerides level (P<0,05) in DM2 with and without NAFLD. Interestingly blood platelets count were found significantly lower in NAFLD group(P<0,001) and Fib4 score were 1.5 times higher (P<0,05) in DM2 group with NAFLD. Analysis of frequency of DM2 complications such as diabetic retinopathy (DR), nephropathy (DN), neuropathy (DPNP) showed more severe stages in NAFLD group. Particularly, DN with proteinuria were detected in 62% with NAFLD and in 35% without; severe DR2 and DR3 were registered in 69% with NAFLD and in 33% without, severe DPNP were diagnosed in 81% with NAFLD and in 74% without NAFLD. Conclusion: NAFLD are frequent future in DM2 and were detected in 45.8% patients, characterized with greater BMI, higher HbA1c, blood fibrinogen and lower platelets number in total blood count and 1.5 times higher Fib4 score. NAFLD associated with more severe stages of diabetes complications and have a great impact on diabetes complication development. no funding This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.